Literature DB >> 2406705

Captopril in children with dilated cardiomyopathy: acute and long-term effects in a prospective study of hemodynamic and hormonal effects.

H Stern1, J Weil, T Genz, W Vogt, K Bühlmeyer.   

Abstract

Hemodynamic and hormonal effects of captopril were prospectively studied in 12 children (median age 5.8 years, range 4 weeks to 15 years) with dilated cardiomyopathy. A mean dose of 1.83 mg captopril/kg body weight was administered in three or four single doses depending on age. Left ventricular volume, ejection fraction (EF), cardiac index (CI), and systemic vascular resistance (SVR) were noninvasively determined by two-dimensional (2D) and Doppler echocardiography before and 2 days and 3 months after the onset of treatment. Blood pressure and heart rate were recorded as well. Additionally, on the day hemodynamic measurements were made, plasma renin activity (PRA), serum aldosterone, and plasma atrial natriuretic peptide (ANP) concentrations were determined. Plasma catecholamines were measured before and 2 days after captopril treatment. Concomitant medication was kept constant during the short-term phase of captopril treatment. During long-term therapy, diuretics were reduced according to the clinical status. Stroke volume (SVI) (-7%), end-systolic (ESVI) (-31%), and end-diastolic (EDVI) (-21%) volume indexes were significantly reduced (p less than 0.05) during short- and long-term therapy. The remaining hemodynamic parameters showed only minor, statistically not significant, changes. During short-term therapy, median serum aldosterone levels fell from 138-88.5 pg/ml (p less than 0.05), and plasma ANP decreased from 144-94 pg/ml (p less than 0.05). After 3 months these effects were less marked and statistically no longer significant. Changes in PRA and plasma catecholamines were not statistically significant at any time.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2406705     DOI: 10.1007/BF02239543

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  38 in total

1.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction.

Authors:  M A Pfeffer; G A Lamas; D E Vaughan; A F Parisi; E Braunwald
Journal:  N Engl J Med       Date:  1988-07-14       Impact factor: 91.245

2.  Limits of reproducibility of blood flow measurements by Doppler echocardiography.

Authors:  E J Meijboom; H Rijsterborgh; H Bot; J A De Boo; J R Roelandt; N Bom
Journal:  Am J Cardiol       Date:  1987-01-01       Impact factor: 2.778

3.  Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failure.

Authors:  D P Faxon; M A Creager; J L Halperin; H Gavras; J D Coffman; T J Ryan
Journal:  Circulation       Date:  1980-05       Impact factor: 29.690

4.  Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study.

Authors:  B L Kramer; B M Massie; N Topic
Journal:  Circulation       Date:  1983-04       Impact factor: 29.690

5.  Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure.

Authors:  M A Creager; J L Halperin; D B Bernard; D P Faxon; C D Melidossian; H Gavras; T J Ryan
Journal:  Circulation       Date:  1981-09       Impact factor: 29.690

6.  [Quantitative study of left ventricular function by two-dimensional echocardiography].

Authors:  P Guéret; E Corday
Journal:  Arch Mal Coeur Vaiss       Date:  1981-03

7.  Echoventriculography -- a simultaneous analysis of two-dimensional echocardiography and cineventriculography.

Authors:  R Erbel; P Schweizer; H Lambertz; G Henn; J Meyer; W Krebs; S Effert
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

8.  Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses.

Authors:  B M Massie; B L Kramer; N Topic
Journal:  Circulation       Date:  1984-06       Impact factor: 29.690

9.  Angiotensin converting enzyme inhibition in patients with congestive heart failure.

Authors:  H Gavras; D P Faxon; J Berkoben; H R Brunner; T J Ryan
Journal:  Circulation       Date:  1978-11       Impact factor: 29.690

10.  Hemodynamic and radionuclide effects of acute captopril therapy for heart failure: changes in left and right ventricular volumes and function at rest and during exercise.

Authors:  B Massie; B L Kramer; N Topic; S G Henderson
Journal:  Circulation       Date:  1982-06       Impact factor: 29.690

View more
  7 in total

Review 1.  Understanding chronic heart failure.

Authors:  Matthew Fenton; Michael Burch
Journal:  Arch Dis Child       Date:  2007-09       Impact factor: 3.791

Review 2.  Advances in heart failure therapy in pediatric patients with dilated cardiomyopathy.

Authors:  Stefan Rupp; Christian Jux
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

Review 3.  Drug Treatment of Heart Failure in Children: Gaps and Opportunities.

Authors:  Molly Weisert; Jennifer A Su; Jondavid Menteer; Robert E Shaddy; Paul F Kantor
Journal:  Paediatr Drugs       Date:  2022-01-27       Impact factor: 3.022

Review 4.  ACE inhibitors in pediatric patients with heart failure.

Authors:  Kazuo Momma
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Efficacy and dosage of enalapril in congenital and acquired heart disease.

Authors:  A M Leversha; N J Wilson; P M Clarkson; A L Calder; M C Ramage; J M Neutze
Journal:  Arch Dis Child       Date:  1994-01       Impact factor: 3.791

6.  Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: a European survey.

Authors:  Cristina Castro Díez; Feras Khalil; Holger Schwender; Michiel Dalinghaus; Ida Jovanovic; Nina Makowski; Christoph Male; Milica Bajcetic; Marijke van der Meulen; Saskia N de Wildt; László Ablonczy; András Szatmári; Ingrid Klingmann; Jennifer Walsh; Stephanie Läer
Journal:  BMJ Paediatr Open       Date:  2019-01-31

7.  Beta-adrenergic receptor antagonists and chronic heart failure in children.

Authors:  Sylvie Di Filippo
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.